Shots:

• The approval is based on P-III OPTIMISMM study results assessing Pomalyst + bortezomib and dexamethasone vs bortezomib + dexamethasone in 559 patients in a ratio (1:1) with 2L+ MM and prior treated with/or refractory to Revlimid (lenalidomide)
• The P-III OPTIMISMM study results: mPFS (11.2 mos. vs 7.1 mos.)- reduction in diseases progression by 39%- patients with 1L therapy- mPFS (20.73 mos. vs 11.63mos.)
• Pomalyst is an immunomodulatory therapy act by enhancing T-cell & NK-cell mediated immunity- indicated to treat MM as triple regimen therapy with Takeda's Velcade (bortezomib) and dexamethasone

Click here to read full press release/ article | Ref: Canada Newswire | Image: QUAPE